The FDA gave priority review to an application seeking approval of AXS-05 for Alzheimer's-related agitation, with a decision ...

There is a rapid growth in the number of people living with Alzheimer’s disease, and only around one in four people with the disease get diagnosed. It is estimated that there are approximately 44 ...

A single oral dose of methylene blue is able to increase the response of brain regions that control attention and short-term memory, according to University of Texas Health Science Center researchers.

Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s ...

Nearly half of Alzheimer’s disease patients treated with TrueBinding’s investigational therapy TB006 for at least three months showed signs of disease reversal or cognitive improvement, according to ...

Alzheimer’s disease affects every aspect of a person’s being, altering personality and behaviors. A loved one diagnosed with dementia may behave irrationally or rudely toward family members, ...

Drinking alcohol, especially in excess, may hinder the brain’s natural ability to clear itself of amyloid beta protein plaques, the underlying cause of Alzheimer’s disease, a study in rat cells ...

Intranasal, or into-the-nose, delivery of foralumab, an investigational antibody-based treatment being developed by Tiziana Life Sciences, restored the activity of microglial cells and improved ...

When Lewis Hornby’s grandmother was rushed to the hospital in 2018, his family feared the worst. Pat Dickinson suffered from dementia, but in this instance it turned out that she was simply dehydrated ...

Treatment with lecanemab (BAN2401), an experimental amyloid-targeting antibody, significantly slowed the progression of dementia symptoms among people with early Alzheimer’s disease in the Phase 3 ...

Dietary supplements with the amino acid L-serine may help reduce memory loss associated with Alzheimer’s disease, a new study suggests. That result was described in the study “Impairment of Glycolysis ...

Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease. “Cassava Sciences is a ...